Elbasvir / grazoprevir
RxNorm 1734635
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1734635 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: elbasvir / grazoprevir.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
MINPrescribable
Multiple Ingredients (MIN):
Elbasvir / grazoprevir
(Atom ID: 7727607)
PTPrescribable
Designated preferred name (PT):
Elbasvir- and grazoprevir-containing product
(Atom ID: 10802023)
FNPrescribable
Full form of descriptor (FN):
Product containing elbasvir and grazoprevir (medicinal product)
(Atom ID: 10810857)
Patient Education
Elbasvir and Grazoprevir
The combination of elbasvir and grazoprevir is used alone or in combination with ribavirin (Copegus, Rebetol, Ribasphere, Virazole) to treat a certain type of chronic (long-term) hepatitis C infection (swelling of the liver caused by a virus). Elbasvir is in a class of antiviral medications called HCV NS5A inhibitors. It works by stopping the virus that causes hepatitis C from spreading inside the body. Grazoprevir is in a class of medications called protease inhibitors. It works by decreasing the amount of hepatitis C virus (HCV) in the body. It is not known if elbasvir and grazoprevir prevent the spread of hepatitis C to other people.
[Learn More]
* Please review the disclaimer below.